Capital and regulators are already backing space-based biomanufacturing. The skilled jobs will gather around the ground-side supply chain, not the orbit.
The crystals that form more cleanly in microgravity are interesting. The places that will capture the skilled jobs and capital around them are more interesting still.
In June 2026 BioOrbit brought back from the International Space Station what UK Research and Innovation later described as the largest-scale production of protein crystals yet achieved in orbit. The six-week run tested a platform intended to turn cancer drugs into concentrated, stable crystals that could be injected at home rather than infused in hospital. The company had raised £9.8 million in April. In September Varda Space Industries closed a $251 million Series D to scale pharmaceutical manufacturing in orbit, and in October Outpost Technologies named the first customer for its Space Factories: an automated laboratory for drug screening in orbit. These are not laboratory curiosities. They are balance-sheet decisions.
The physical process is well understood. Without sedimentation or convection currents, protein crystals can grow more uniformly than on Earth. Merck demonstrated the effect years ago with Keytruda. What has changed is the cost of access and the existence of private vehicles that return material rather than discard it. Once a crystal or a processed batch can be brought back under controlled conditions, the experiment becomes a manufacturing step. The United Kingdom has noticed. In March 2026 the UK Space Agency, MHRA, Regulatory Innovation Office and Civil Aviation Authority issued a joint statement on in-orbit manufacturing and announced a re-entry regulatory sandbox. The UK’s approach is deliberately non-prescriptive and outcome-focused: operators must show that risks, including those of re-entry with pharmaceutical cargo, are as low as reasonably practicable. That is the language of industrial licensing, not science outreach.
Most economic-development strategies still treat the field as a distant research theme. They are looking at the wrong altitude. The orbital step is short. The capital and the skilled labour will concentrate on the ground: formulation development, analytical method validation, quality systems that satisfy both pharmaceutical and spaceflight regulators, cold-chain and ambient-preservation logistics that survive launch and re-entry, and the clinical-supply infrastructure that turns a returned crystal into a trial-ready dose. BioOrbit’s own near-term path runs through regulatory dialogue with the MHRA and the UK Space Agency; Varda’s commercial cadence depends on repeatable recovery and downstream processing. The companies that win those contracts will sit next to the laboratories, the contract manufacturers and the regulatory talent that already exist in a handful of places.
Regions that already combine a strong life-sciences manufacturing base with space-access infrastructure therefore hold a temporary advantage. The window is not measured in decades. Private capital is committing now precisely because the technical risk has fallen enough for the remaining uncertainties—crystal integrity through re-entry, batch-to-batch consistency, and the first clinical protocols—to be underwritten. An agency that waits for a mature orbital factory will find the supporting supply chain already spoken for. The practical work is to map existing formulation and quality capacity against the specific needs of recoverable microgravity processing, to engage the medicines regulator on the sandbox, and to treat re-entry logistics as an industrial capability rather than an exotic service.
The science will continue to improve. The location decisions will not wait for it.
LibLeo works with economic development organisations on the skilled-jobs and capital outcomes of BioSpace and related industrial bases.